

ABSTRACT

[00171] Methods and kits for diagnosing tumorigenicity and for determining whether a cancer patient is resistant to the pharmacological effects of antiestrogen therapy . Increased levels of the PCDGF (GP88) growth factor are indicative of tumorigenicity and resistance to the pharmacological effects of antiestrogen therapy. The methods and kits of the invention are useful for assessing the tumorigenicity of a biological sample from a patient and determining whether the patient is a candidate for antiestrogen, including tamoxifen, therapy.